Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals.
Radiopharmaceuticals are a growing class of medicines that contain radioactive forms of chemical elements (called radioisotopes) that effectively diagnose and treat cancers. They provide a rapidly advancing approach to the future of medical research and treatments, with the potential to drive game-changing breakthroughs for patients.
When used in oncology, radiopharmaceuticals deliver therapeutic radiation directly to tumors, meaning that they are more targeted, more effective, and result in fewer side effects. Radiopharmaceuticals can also be used as radioactive tracers in medical imaging, enhancing accuracy and providing detailed insights to help improve diagnosis.
The strategic global collaboration between MDC and Crown Bioscience supports companies across the radiopharmaceutical pipeline, whether they are advancing radiotherapeutics, exploring new isotopes, or optimizing targeting agents.
It recognizes and leverages the complementarity between MDC and Crown Bioscience’s expertise and technology platforms, and creates value for global life sciences companies, by providing access to an integrated, clinically relevant platform for evaluating their radiopharmaceutical therapies. MDC brings expertise and cutting-edge technology to the partnership in the fields of cell biology, high-resolution microscopy, radiochemistry, preclinical imaging, mass spectrometry and multi-omic tissue analysis enabling a comprehensive analysis of radiopharmaceutical assets.
The collaboration enables rapid and reliable testing of how radiopharmaceuticals work, how the body responds to them, and how effective they are – all critical factors in identifying viable drug candidates early and reducing clinical development risk.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!